Blocking the renin-angiotensin system: Dual-versus mono-therapy

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 6, 2009, Pages 667-674

  Ravandi, Amir ^a   Teo, Koon K ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Acute coronary syndrome; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Dual therapy; Heart failure

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; NITRIC OXIDE; PERINDOPRIL; PLACEBO; PROSTACYCLIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PLEIOTROPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; DRUG EFFECT; PATHOPHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 68649128077     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.47     Document Type: Review

References (59)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary-artery disease - a workshop consensus statement. Am. Heart J. 121(4), 1244-1263 (1991).
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217-223 (2005).
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913 (2002).
4. Dielis AWJH, Smid M, Spronk HMH et. al. The prothrombotic paradox of hypertension - role of the renin - angiotensin and kallikrein - kinin systems. Hypertension 46(6), 1236-1242 (2005).
5. Peach MJ. Renin - angiotensin system - biochemistry and mechanisms of action. Physiol. Rev. 57(2), 313-370 (1977).
6. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure - the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
7. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Hear Fail. Rev. 10(1), 31-37 (2005).
8. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue - evidence from comparative pharmacological interruption of the renin system. Hypertension 32(3), 387-392 (1998).
9. Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J. Hypertens. Suppl. 24(1), S15-S21 (2006).
10. 1-type angiotensin receptor in oxidative stress and atherogenesis part I: oxidative stress and atherogenesis. Circulation 105(3), 393-396 (2002).
11. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp. Physiol. 90(4), 449-455 (2005).
12. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J. Cardiovasc. Pharm. 44(3), 335-339 (2004).
13. 1 receptor regulation. Circulation 105(4), 530-536 (2002).
14. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104(2), 191-196 (2001).
15. Schulman IH, Zhou MS, Raij L. Crosstalk between angiotensin II receptor types 1 and 2 - potential role in vascular remodeling in humans. Hypertension 49(2), 270-271 (2007).
16. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides 26(8), 1401-1409 (2005).
17. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme-inhibition in human-subjects. Clin. Sci. 87(5), 567-574 (1994).
18. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95(5), 1115-1118 (1997).
19. Hoppe UC. Treatment of heart failure with ACE inhibitors and β-blockers - what is next? AT1-receptor antagonists? Clin. Res. Cardiol. 96(4), 196-198 (2007).
20. Ibrahim MM. RAS inhibition in hypertension. J. Hum. Hypertens. 20(2), 101-108 (2006).
21. MacFadyen RJ, Lee AFC, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82(1), 57-61 (1999).
22. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques - potential implications for inflammation and plaque instability. Circulation 101(12), 1372-1378 (2000).
23. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342(3), 145-153 (2000).
24. Fox KM, Bertrand M, Ferrari R et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362(9386), 782-788 (2003).
25. Braunwald E, Pfeffer MA, Domanski M et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351(20), 2058-2068 (2004).
26. Pepine C, Probstfield J. A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients. Vasc. Biol. Clin. Pract. 6(3) (2004).
27. Pitt B, O'Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (OUIET): Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol. 87(9), 1058-1063 (2001).
28. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368(9535), 581-588 (2006).
29. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008).
30. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349(20), 1893-1906 (2003).
31. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112(12), E154-E235 (2005).
32. AIRE Study Investigators. The Acute Infarction Ramipril Efficacy (AIRE) study. Circulation 88(4), 394-394 (1993).
33. Swedberg K. Effects of enalapril on mortality in severe congestive-heart-failure - results of the cooperative-north-scandinavian-enalapril-survival-study (consensus). N. Engl. J. Med. 316(23), 1429-1435 (1987).
34. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355(9215), 1575-1581 (2000).
35. Yusuf S. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive-heart-failure. N. Engl. J. Med. 325 (5), 293-302 (1991).
36. Nicklas JM, Pitt B, Timmis G et al. Effect of enalapril on mortality and the development of heart-failure in asymptomatic patients with reduced left-ventricular ejection fractions. N. Engl. J. Med. 327(10), 685-691 (1992).
37. Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial-infarction and unstable angina in patients with low ejection fractions. Lancet 340(8829), 1173-1178 (1992).
38. Ball SG, Cowan JC, Winter C et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial-infarction with clinical-evidence of heart-failure. Lancet 342(8875), 821-828 (1993).
39. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 354(9172), 9-12 (1999).
40. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345(23), 1667-1675 (2001).
41. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362(9386), 772-776 (2003).
42. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 362(9386), 759-766 (2003).
43. McMurray JJV, Ostergran J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9386), 767-771 (2003).
44. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355(9215), 1582-1587 (2000).
45. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324(7339), 699-702 (2002).
46. Lithell H, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 22(8), 1605-1612 (2004).
47. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9292), 1556-1556 (2001).
48. Yusuf S, Diener H, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359(12), 1225-1237 (2008).
49. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353(9153), 611-616 (1999).
50. Stearne MR, Palmer SL, Hammersley MS et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. BMJ 317(7160), 713-720 (1998).
51. Schmieder RE. Endotheiial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J. Hypertens. 24, S31-S35 (2006).
52. Parving HH, Lehnert H, Brochner-Mortenseh J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 345(12), 870-878 (2001).
53. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351 (19), 1941-1951 (2004).
54. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - a randomized controlled trial. JAMA 285(21), 2719-2728 (2001).
55. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12), 861-869 (2001).
56. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345(12), 851-860 (2001).
57. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. 351(19), 1952-1961 (2004).
58. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638), 547-553 (2008).
59. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. AVOID Study investigators. N. Engl. J. Med. 358, 2433-2446 (2008).